Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.

Xbrane Biopharma AB (publ)

Xbrane Biopharma develops biosimilars for the treatment of macular degeneration, rheumatoid arthritis, psoriasis, and cancer with a focus on making biological drugs more accessible. Self-described as a biosimilar developer.

msh id	COM:XBRANE
symbol	XBRANE
name	Xbrane Biopharma AB (publ)
homepage url	https://www.xbrane.com
country	SE
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	75
crunchbase url	-
linkedin url	-
founders	-

market cap	31.81M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	1.61
growth cost of revenue	11.27
growth depreciation and amortization	116.55
growth ebitda	-0.67
growth ebitda ratio	0.6
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-1
growth gross profit	-0.14
growth gross profit ratio	-0.79

XBRA

COM:XBRANE

Xbrane Biopharma

Last Close

0.20

21/11 16:29

Market Cap

339.03M

Beta: -

Volume Today

8.50M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	50.65M
cost of revenue	50.65M
depreciation and amortization	3.11M
ebitda	-25.52M
ebitda ratio	-1.16
eps	-0.14
eps diluted	-0.14
operating expenses	31.9M
operating income	-28.63M
operating income ratio	-1.3

accounts receivables	-7.85M
capital expenditure	-1.55M
cash at beginning of period	17.89M
cash at end of period	6.03M
inventory	9.86M
working capital ttm	296.51M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-